Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2022

View Archived Issues

Novel Fanconi anemia xenograft murine model to test immunotherapy

Allorion Therapeutics presents TYK2 inhibitor ARTS-011 for the treatment of inflammatory disease

Autoantibody-induced murine dry eye disease model mimics human disease

Novel Nr1h3-/- mouse model exhibits AMD-like pathology

MFAP4 as a novel target in choroidal neovascularization

Across body parts, "parts list" gives insights into the lives of a cell

Chinese investigators patent new HIF inhibitors

Medivir and Rheos Medicines divulge new MALT1 inhibitors

U.S. researchers describe new PROTACs for cancer

Johns Hopkins University synthesizes MAP3K12/13 inhibitors

Chinese researchers disclose new CDK9 inhibitors

Kymera presents preclinical data on STAT3 degrader KTX-115

VERVE-101 shows durable editing of PCSK9 gene; GalNAc-LNPs improve delivery of base editors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.